Barasertib (AZD1152-HQPA)

For research use only. Not for use in humans.

製品コードS1147 別名:AZD2811

Barasertib (AZD1152-HQPA)化学構造

分子量(MW):507.56

Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 29800 あり
JPY 21900 あり
JPY 36800 あり
JPY 113200 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(65)

製品安全説明書

Aurora Kinase阻害剤の選択性比較

生物活性

製品説明 Barasertib (AZD1152-HQPA) is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, ~3700 fold more selective for Aurora B over Aurora A. Phase 1.
ターゲット
Aurora B [1]
(Cell-free assay)
0.37 nM
体外試験

AZD1152 displays >3000-fold selectivity for Aurora B as compared with Aurora A which has an IC50 of 1.368 μM. AZD1152 has even less activity against 50 other serine-threonine and tyrosine kinases including FLT3, JAK2, and Abl. AZD1152 inhibits the proliferation of hematopoietic malignant cells such as HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, and K562 cells with IC50 of 3-40 nM, displaying ~100-fold potency than another Aurora kinase inhibitor ZM334739 which has IC50 of 3-30 μM. AZD1152 inhibits the clonogenic growth of MOLM13 and MV4-11 cells with IC50 of 1 nM and 2.8 nM, respectively, as well as the freshly isolated imatinib-resistant leukemia cells with IC50 values of 1-3 nM, more significantly compared with bone marrow mononuclear cells with IC50 values of >10 nM. AZD1152 induces accumulation of cells with 4N/8N DNA content, followed by apoptosis in a dose- and time-dependent manner. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofLNE02ODBibl2= M{HISVQ5yqCq MYPJR|UxRTJ3IH7N M3m1flI2Ojd5NkW5
LNCaP MonORZBweHSxc3nzJGF{e2G7 M2PpeVAuPTByIH7N M4fBcFQ5yqCq MXHpcoR2[2W|IHHwc5B1d3SrYzDj[YxtKGSnYYToJJRpem:3Z3igZ4F{eGG|ZT2zJJVxemWpdXzheIlwdg>? MVKyOVI4PzZ3OR?=
LNCaP MmHiSpVv[3Srb36gRZN{[Xl? NILqUog2OCCwTR?= NVLo[Yd2PDhiaB?= NFHyTIVqdmS3Y3XzJI1q[3KxboXjcIVqKHerdHigZY5mfWenbnnjJI1m[2ijbnnzcS=> NFrHV3kzPTJ5N{[1PS=>
Ramos MVTGeY5kfGmxbjDBd5NigQ>? MlrJOVAxKG6P MYCwMVczKGh? NUPZWHpNcW6qaXLpeJMhSXW{b4LhJGIhc2mwYYPl MVyyNVM4OTR2Nh?=
Daudi  M3PxNWZ2dmO2aX;uJGF{e2G7 NHm2UIc2ODBibl2= NFHwPXMxNTd{IHi= MkTVbY5pcWKrdIOgRZVzd3KjIFKgb4lv[XOn MUOyNVM4OTR2Nh?=
L540 M2TBUGZ2dmO2aX;uJGF{e2G7 MnLxOVAxKG6P NWfJN4dJOC15MjDo MXvpcohq[mm2czDBeZJwemFiQjDrbY5ie2V? MkXyNlE{PzF2NE[=
BJAJ M3jo[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULEN3RyPTByIH7N MmDYNE04OiCq NX;lNnppcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> Mn6yNlE{PzF2NE[=
Ramos M{L5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHaVnU2ODBibl2= NVHxfnZJOC15MjDo MonLbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NHHjZZozOTN5MUS0Oi=>
Raji MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG1NFAhdk1? MmrINE04OiCq MXTpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 M{nXd|IyOzdzNES2
Daudi  NGDyd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLuOVAxKG6P Mk\PNE04OiCq MlH3bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= MX6yNVM4OTR2Nh?=
L428 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DVR|UxOCCwTR?= Mo\mNE04OiCq MlXabY5pcWKrdIOgZ4VtdCCpcn;3eIg> MYCyNVM4OTR2Nh?=
KM-H2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{niOFUxOCCwTR?= NGHkPG8xNTd{IHi= NVy0e2ZQcW6qaXLpeJMh[2WubDDndo94fGh? MnvwNlE{PzF2NE[=
HDLM-2 NFP6[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTMOVAxKG6P NVjvbIpkOC15MjDo NGfyOoVqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MoKwNlE{PzF2NE[=
L450 NEHqcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlGzOVAxKG6P M4PnVFAuPzJiaB?= NIm4dHRqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NH7lTFkzOTN5MUS0Oi=>
BJAJ M13LN2Fxd3C2b4Ppd{BCe3OjeR?= M3OzeFUxOCCwTR?= M{jGPFAuPzJiaB?= NV\HSYRycW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> M32yW|IyOzdzNES2
Ramos M{O2dGFxd3C2b4Ppd{BCe3OjeR?= M2PVdFUxOCCwTR?= NFLtSY4xNTd{IHi= MYnpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NUnodYo2OjF|N{G0OFY>
Raji MoP0RZBweHSxc3nzJGF{e2G7 MX21NFAhdk1? NHjhVmcxNTd{IHi= M{PYUYlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy MoXBNlE{PzF2NE[=
Daudi  M3rNPGFxd3C2b4Ppd{BCe3OjeR?= NV64dWs5PTByIH7N NGXsXosxNTd{IHi= M2jITolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy M2P5SVIyOzdzNES2
L428 MVjBdI9xfG:|aYOgRZN{[Xl? NFjaNHI2ODBibl2= MXGwMVczKGh? NVHGNWlWcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MmfBNlE{PzF2NE[=
KM-H2 MkG4RZBweHSxc3nzJGF{e2G7 MoT0OVAxKG6P MXiwMVczKGh? NIjZd21qdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NXrSNWJJOjF|N{G0OFY>
HDLM-2 NEXQcohCeG:ydH;zbZMhSXO|YYm= NVjrO3hWPTByIH7N Ml7XNE04OiCq NU\MSZpFcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MXmyNVM4OTR2Nh?=
L450 NEO1ZndCeG:ydH;zbZMhSXO|YYm= MUm1NFAhdk1? M3;udFAuPzJiaB?= NVHDOGRjcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NUn1SIJLOjF|N{G0OFY>
SW620 M1m5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rLeGVEPTB;MUFCtVIvOSCwTR?= MXmyNVI1PTB7MB?=
HCT116 M{f2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfFR|UxRTFzwsGzMlMhdk1? NFfGW|IzOTJ2NUC5NC=>
MDA-MB-435 NGjoNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSwMVExODByIH7N Ml\MNk02KGR? NHzwSmFFVVOR NFvJW45KSzVyPUGyOUBvVQ>? M3HROFIxOTd3OUK2
MDA-MB-468 NHzWXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjyWZExNTFyMECwJI5O NHOzc|IzNTViZB?= MlHSSG1UVw>? MVHJR|UxRTF2IH7N MV6yNFE4PTl{Nh?=
MDA-MB-231 M3O3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGwMVExODByIH7N MmjCNk02KGR? M2nISGROW09? MmnkTWM2OD1zMEWgcm0> M{[1Z|IxOTd3OUK2
BT474 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuwMVExODByIH7N MXqyMVUh\A>? NWHaRmpOTE2VTx?= MlHaTWM2OD16IH7N NXP5TmlWOjBzN{W5NlY>
MDA-MB-361 M{TOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLKSVd{OC1zMECwNEBvVQ>? M1PIN|IuPSCm MmfhSG1UVw>? MWnJR|UxRTdyIH7N MWSyNFE4PTl{Nh?=
HER18 NXPsc|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqwMVExODByIH7N MmruNk02KGR? M4K3VWROW09? M1\hSWlEPTB;MkCgcm0> NHzHbGgzODF5NUmyOi=>
HER18 MXvBdI9xfG:|aYOgRZN{[Xl? Ml:yNVAxKG6P MWCwM|I1NzR6IHi= NXfD[IhKTE2VTx?= MnThbY5lfWOnczDhdI9xfG:|aYOgZY5lKHKnZIXj[ZMh[2yxbn;n[Y5q[yCyb4TlcpRq[Wx? NFK2cnkzODF5NUmyOi=>
MDA-MB-231 NEfjPIpCeG:ydH;zbZMhSXO|YYm= NIr2O|gyODVibl2= NX7zZW9DOC9{ND:0PEBp NYfqVYdrTE2VTx?= NYK0cHM5cW6mdXPld{BieG:ydH;zbZMh[W6mIILl[JVk\XNiY3zvco9o\W6rYzDwc5RmdnSrYXy= MlnGNlAyPzV7Mk[=
JHH-1 NUCwS2VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXDS2d6OC5|4pETNVAxOMLibl2= MYq3NkBp MmLsSWM2OD1zNz60xtEyNjBibl2= MlvPNVk6OTN7M{W=
JHH-2 M{X5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLGUlVIOC5|4pETNVAxOMLibl2= M33oOFczKGh? M2G2WGVEPTB;MkG4MlDDuTFyLkigcm0> NFTKS3YyQTlzM{mzOS=>
JHH-4 M3zIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHtNE4{6oDVMUCwNOKhdk1? NHfUUZg4OiCq M3PxVWVEPTB;MUW1MlbDuTF4Lkigcm0> NXnPRWdbOTl7MUO5N|U>
HuH-1 MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSzXJMxNjQkgKOxNFAxyqCwTR?= MYW3NkBp NWTBbXlWTUN3ME2yO{4{yrF3LkCgcm0> NH7q[lQyQTlzM{mzOS=>
HuH-6 NW\YUnlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmwMlPjiJNzMECwxsBvVQ>? M2mzPFczKGh? MmD2SWM2OD1|LkhCtVAvPiCwTR?= M171WFE6QTF|OUO1
HuH-7 NUGwTVMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLTNE4{6oDVMUCwNOKhdk1? NVvBb|E4PzJiaB?= NIHnNmVGSzVyPU[uPOKyOC5|IH7N NVP2[|Y{OTl7MUO5N|U>
HLE NYjjNm5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXUNE4{6oDVMUCwNOKhdk1? NY\qRpN{PzJiaB?= NXviXmlsTUN3ME20OU46yrF4LkSgcm0> NIniVlIyQTlzM{mzOS=>
HLF NYfuSoNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\iVnIxNjQkgKOxNFAxyqCwTR?= NH\Q[XE4OiCq NHW5WXFGSzVyPUGyOk4yyrFzMj6yJI5O M2jGTVE6QTF|OUO1
PLC/PRF/5 NUfUXpQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moj0NE4{6oDVMUCwNOKhdk1? NWT3eXBRPzJiaB?= NWTsWmIxTUN3ME23Ok46yrF7Lkmgcm0> NEnZPVMyQTlzM{mzOS=>
SK-Hep1 NIXvS4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLvNE4{6oDVMUCwNOKhdk1? M4P4RlczKGh? NUjzdHdlTUN3ME2yNU46yrFzLkKgcm0> MV:xPVkyOzl|NR?=
Hep3B M1rrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVqwMlPjiJNzMECwxsBvVQ>? MVO3NkBp MlfHSWM2OD15LkdCtVEvOiCwTR?= NEi2[3cyQTlzM{mzOS=>
HepG2 M1nQO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXewZ2RmOC5|4pETNVAxOMLibl2= Mk\YO|IhcA>? MWLFR|UxRTF2LkhCtVEvPyCwTR?= NW\aeI5NOTl7MUO5N|U>
Ramos M4r6TWFxd3C2b4Ppd{BCe3OjeR?= M1\Re|I2NzVyL{GwNEBvVQ>? NVXSNHFlPDhiaB?= M1v4b4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> NF7CU5UyQTh{M{G2PC=>
Daudi  Mn\JRZBweHSxc3nzJGF{e2G7 M2XPSVI2NzVyL{GwNEBvVQ>? MX:0PEBp M3PRdYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBkdGWjdnXkJIZwem2|IH;mJHBCWlBiYX7kJINie3Cjc3WgNy=> M2fjT|E6QDJ|MU[4
BALM-14 NXXqd|FHSXCxcITvd4l{KEG|c3H5 NW[2VlhxOTJwNT:yOU82OCCwTR?= MlXvOFghcA>? NF;VN|FqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> NUL1boV[OTl6MkOxOlg>
BALM-27 NYTtbJpJSXCxcITvd4l{KEG|c3H5 NGPlT3cyOi53L{K1M|UxKG6P NXW5OHllPDhiaB?= Mkj5bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG|ZTCz NVXPToF1OTl6MkOxOlg>
NB4 NFLlVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PtXVAvODFxMD6xM|Eh|ryP Ml\hOFghcA>? MXXpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 M1jSWlE5OzZ5NEi0

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN; 

PubMed: 26497213     


Downstream effects of barasertib-induced AURKB inhibition on histone H3 phosphorylation and TP53 protein levels in IMR5 and SK-N-BE (2c) as indicated after 24h (left) and 48h (right). TP53 and its downstream effector CDKN1A were up-regulated by barasertib䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

p53 / p21 / p-p38 / p38 ; 

PubMed: 24782314     


U2OS cells were treated with 50 nm or 100 nm AZD1152 for 24 h. p21, p38, p-p38, and p53 levels were determined by immunoblotting β-actin served as a loading control.

26497213 24782314
Immunofluorescence
p21 ; 

PubMed: 24782314     


U2OS cells were treated as in H. Levels of p21 were analyzed by immunostaining. DNA was counterstained with Hoechst 33258.

24782314
Growth inhibition assay
Cell viability ; 

PubMed: 26497213     


Dose response curves to barasertib at 72h of incubation normalized to the DMSO control sample (mean ± SD, n = 5). The inset depicts the normalized AUCs of each response curve. 

26497213
体内試験 Administration of AZD1152 (25 mg/kg) alone markedly suppresses the growth of MOLM13 xenografts, confirmed by the observation of necrotic tissue with infiltration of phagocytic cells. [1] In addition, AZD1152 (10-150 mg/kg/day) significantly inhibits the growth of a variety of human solid tumor xenografts, including colon, breast, and lung cancers, in a dose-dependent manner. [2]

お薦めの試験操作(参考用のみ)

細胞試験: [1]
- 合併
  • 細胞株: HL-60, NB4, MOLM13, PALL-2, MV4-11, EOL-1, and K562 cells
  • 濃度: Dissolved in DMSO, final concentrations ~100 nM
  • 反応時間: 24 or 48 hours
  • 実験の流れ: Cells are exposed to various concentrations of AZD1152 for 24 or 48 hours. Cell proliferation is measured by 3H-thymidine uptake (isotope added 6 hours before harvest), and the concentration that induced 50% growth inhibition (IC50) is calculated from dose-response curves. Cell cycle analysis is performed by flow cytometry. Cell apoptosis is measured by annexin V–FITC apoptosis detection kit.
    (参考用のみ)
動物試験:[1]
- 合併
  • 動物モデル: Female immune-deficient BALB/c nude mice subcutaneously injected with MOLM13 cells
  • 投薬量: 5 or 25 mg/kg
  • 投与方法: Intraperitoneal injection 4 times a week or every another day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 102 mg/mL (200.96 mM)
Ethanol 3 mg/mL (5.91 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
7mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 507.56
化学式

C26H30FN7O3

CAS No. 722544-51-6
Storage powder
in solvent
別名 AZD2811
Smiles CCN(CCO)CCCOC1=CC=C2C(=NC=NC2=C1)NC3=CC(=N[NH]3)CC(=O)NC4=CC=CC(=C4)F

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

  • 回答:

    S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

Aurora Kinaseシグナル伝達経路

Aurora Kinase Inhibitors with Unique Features

相関Aurora Kinase製品

Tags: Barasertib (AZD1152-HQPA)を買う | Barasertib (AZD1152-HQPA) ic50 | Barasertib (AZD1152-HQPA)供給者 | Barasertib (AZD1152-HQPA)を購入する | Barasertib (AZD1152-HQPA)費用 | Barasertib (AZD1152-HQPA)生産者 | オーダーBarasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA)化学構造 | Barasertib (AZD1152-HQPA)分子量 | Barasertib (AZD1152-HQPA)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID